Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: They will receive 300g of probiotic yogurt enriched with Bifidobacterium lactis and Lactobacillus acidophilus strains daily for 12 weeks. Microbiological analyzes s
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Non-alcoholic fatty liver disease was approved by a gastroenterologist using fibroscan examination Individuals aged 20 to 60 years Patients have a fixed plan for medication use during the last 3 months Body mass index between 25 to 35 kg/m 2
Exclusion criteria
Exclusion criteria: Smokers History of alcohol consumption Adherence to a special diet in the last 3 months Pregnant or lactating women or those planning to get pregnant in the next three months Menopausal women Individuals with pathologic conditions affecting the liver, including acute and chronic hepatitis, viral hepatitis, liver transplantation, autonomic hepatitis, hemochromatosis, primary biliary cirrhosis, Wilson's disease, antitrypsin deficiency and thyroid disease People with lactose intolerance People taking antibiotics patients taking medications affecting serum lipids Individuals taking multivitamin-minerals during the previous month Patients who have used any type of probiotic product in the last two months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic steatosis. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Fibro-scan.;Hepatic fibrosis. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Fibro-scan.;Liver enzyme (ALT, AST and GGT). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profile (TG, Total cholesterol, LDL-c and LDH-c). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.;Glycemic index (FBS, FBI, HOMA-IR and QUICKI). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.;Weight. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Scales.;Waist circumference. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Tape meter.;Body mass index (BMI). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Formula (weight (kilograms) divided by the squared height (meters)). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSara Ebrahimi-Mousavi
Tehran University of Medical Sciences
Outcome results
None listed